Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
At least 36 dead in major fire in Hong Kong residential blocks - 26 Hints to Upgrade Your Appeal, In addition to Your Outlook
- 3US EPA will reassess safety of herbicide paraquat, says its chief
- 4Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 5Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- The Fate of Rest: Patterns in Shrewd Beds
- The Best 15 Applications for Efficiency and Association
- Kiev declares energy emergency after Russian attacks amid winter cold
- Bavarian leader questions Germany's Eurovision participation
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- New UPS distribution center in Taiwan doubles capacity, productivity
- The Best Web-based Courses for Ability Advancement
- Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
- Major railway disruptions persist as Germany braces for more snow
